BASEL, Switzerland, Jan. 18, 2024 /PRNewswire/ -- Synendos Therapeutics AG (Synendos), a world leader in innovative Endocannabinoid System (ECS) treatments, today announces that it has received approval from the European Medicines Agency (EMA) to commence the Phase 1 'first-in-human' clinical trial of its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the Endocannabinoid System to restore healthy brain physiology.
BASEL, Switzerland, July 18, 2023 /PRNewswire/ -- Synendos Therapeutics AG (Synendos), a world leader in innovative Endocannabinoid System (ECS) treatments, today announces that its co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, last night presented new findings on the endocannabinoid transporter at the 10th Gordon Research Conference on 'Cannabinoid Function in the CNS - Charting the Course to Novel Therapeutics from a Fundamental Understanding of Cannabinoid Neurobiology'.
BASEL, Switzerland, April 20, 2021 /PRNewswire/ -- Synendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat Central Nervous System (CNS) disorders, today announces an extension to its Series A financing with the addition of Ysios Capital to its syndicate of European investors. Ysios Capital's contribution brings the total raised to CHF 24 million, following a Series A financing co-led by Kurma Partners and Sunstone Life Science Ventures announced in November 2020.
BASEL, Switzerland, April 20, 2021 /PRNewswire/ -- Synendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat Central Nervous System (CNS) disorders, today announces an extension to its Series A financing with the addition of Ysios Capital to its syndicate of European investors. Ysios Capital's contribution brings the total raised to CHF 24 million, following a Series A financing co-led by Kurma Partners and Sunstone Life Science Ventures announced in November 2020.